VIVUS, Inc. (VVUS)

3.53
0.12 3.28
NASDAQ
Prev Close 3.65
Open 3.61
Day Low/High 3.52 / 3.64
52 Wk Low/High 2.15 / 9.88
Volume 32.27K
Exchange NASDAQ
Shares Outstanding 10.64B
Market Cap 38.83M
Div & Yield N.A. (N.A)
Qsymia Shown To Reduce Progression To Type 2 Diabetes In High-Risk Overweight Or Obese Patients

Qsymia Shown To Reduce Progression To Type 2 Diabetes In High-Risk Overweight Or Obese Patients

Weight Loss With Qsymia Reduced Annualized Incidence Rate of Type 2 Diabetes Up to 78%

Companies Ripe for Activism

Companies Ripe for Activism

Hedge fund manager Gregory Taxin of Clinton Group talks about when companies hit a critical point that makes them ripe for activism.

2 Ways to Play Vivus

2 Ways to Play Vivus

The short-term picture has changed.

Viva La Vivus?

Viva La Vivus?

This looks ready to make a move higher.

Trade-Ideas: Vivus (VVUS) Is Today's "Barbarian At The Gate" Stock

Trade-Ideas: Vivus (VVUS) Is Today's "Barbarian At The Gate" Stock

Trade-Ideas LLC identified Vivus (VVUS) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

Beware of 'Earnings Torpedos'

Some of the market's favorite stocks have entered a danger zone.

Biotech Stock Mailbag: Ariad, NewLink, Zogenix, 5 Falling Stocks For Rest of '13

Biotech Stock Mailbag: Ariad, NewLink, Zogenix, 5 Falling Stocks For Rest of '13

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Another VIVUS CEO Could Be Good News For This Stock

Another VIVUS CEO Could Be Good News For This Stock

Chris Lao, Kapitall: Biotech company VIVUS just named another new CEO, so who stands to benefit from the change? The resignation [...]

Insider Trading Alert - Middleby Corporation And 4 Others Traded By Insiders

Insider Trading Alert - Middleby Corporation And 4 Others Traded By Insiders

Stocks with insider trader activity include MIDD, VVUS, N, KS and RJF

The Deal: Vivus Considers Next Steps With Big Pharma Partners

The Deal: Vivus Considers Next Steps With Big Pharma Partners

New CEO Tony Zook has tough job, but investors optimistic.

Ask SUT

This week, David Peltier answers questions from two subscribers about a pharmaceutical stock and a banking name.

Vivus Weight-Loss Pill Scripts Are Surging

Vivus Weight-Loss Pill Scripts Are Surging

An acceleration in Qsymia script growth started when Vivus gained access to retail pharmacies.

3 Things To Watch For With Arena Pharmaceuticals

3 Things To Watch For With Arena Pharmaceuticals

When Jefferies released a research note for Arena Pharmaceuticals (ARNA) with a target price of $12, shares subsequently fell to [...]

VIVUS Board Selects Michael Astrue As Chairman And Tony Zook As CEO

VIVUS Board Selects Michael Astrue As Chairman And Tony Zook As CEO

New Team Pledges Fast Action to Bring Anti-Obesity Drug Qsymia to More Patients

One Short Seller's Take On Arena's Slow Belviq Launch

One Short Seller's Take On Arena's Slow Belviq Launch

Arena's weight-loss pill is only performing as well as Vivus' -- and that's not good enough.

First Manhattan Continues To Seek Fair Settlement

First Manhattan Continues To Seek Fair Settlement

First Manhattan Co. (“FMC”), an owner-managed and operated investment advisory firm and the owner of approximately 9.

First Manhattan Continues To Seek Settlement Despite Bad Faith Negotiating Tactics From Vivus’ Existing Board

First Manhattan Continues To Seek Settlement Despite Bad Faith Negotiating Tactics From Vivus’ Existing Board

First Manhattan Co. (“FMC”), an owner-managed and operated investment advisory firm and the owner of approximately 9.

First Manhattan Asks Delaware Court To Certify Results Of Vivus’ Annual Meeting

First Manhattan Asks Delaware Court To Certify Results Of Vivus’ Annual Meeting

First Manhattan Co. (“FMC”), an owner-managed and operated investment advisory firm and the owner of approximately 9.

First Manhattan Objects To Adjournment Of Vivus Annual Meeting

First Manhattan Objects To Adjournment Of Vivus Annual Meeting

First Manhattan Co. (“FMC”), an owner-managed and operated investment advisory firm and the owner of approximately 9.

First Manhattan Calls Adjournment Of Annual Meeting By The Vivus Board A Desperate Act To Disenfranchise Shareholders

First Manhattan Calls Adjournment Of Annual Meeting By The Vivus Board A Desperate Act To Disenfranchise Shareholders

First Manhattan Co. (“FMC”), an owner-managed and operated investment advisory firm and the owner of approximately 9.

TheStreet Quant Rating: D (Sell)